• 1.

    Vaidya A, et al.. The unrecognized prevalence of primary aldosteronism. Ann Intern Med 2020; 173:683. doi: 10.7326/L20-1097

  • 2.

    Monticone S, et al.. Prevalence and clinical manifestations of primary aldosteronism encountered in primary care practice. J Am Coll Cardiol 2017; 69:18111820. doi: 10.1016/j.jacc.2017.01.052

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 3.

    Paolo Rossi G, et al.. A prospective study of the prevalence of primary aldosteronism in 1,125 hypertensive patients. J Am Coll Cardiol 2006; 48:22932300. doi: 10.1016/j.jacc.2006.07.059

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 4.

    Calhoun DA, et al.. Hyperaldosteronism among black and white subjects with resistant hypertension. Hypertension 2002; 40:892896. doi: 10.1161/01.hyp.0000040261.30455.b6

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 5.

    Hundemer GL, et al.. Cardiometabolic outcomes and mortality in medically treated primary aldosteronism: A retrospective cohort study. Lancet Diabetes Endocrinol 2018; 6:5159. doi: 10.1016/S2213-8587(17)30367-4

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 6.

    Byrd JB, et al.. Primary aldosteronism: Practical approach to diagnosis and management. Circulation 2018; 138:823835. doi: 10.1161/CIRCULATIONAHA.118.033597

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 7.

    Funder JW, et al.. The management of primary aldosteronism: Case detection, diagnosis, and treatment: An Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2016; 101:18891916. doi: 10.1210/jc.2015-4061

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 8.

    Whelton PK, et al.. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: Executive Summary: A report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Hypertension 2018; 71:12691324. doi: 10.1161/HYP.0000000000000066

    • Search Google Scholar
    • Export Citation
  • 9.

    Jaffe G, et al.. Screening rates for primary aldosteronism in resistant hypertension: A cohort study. Hypertension 2020; 75:650659. doi: 10.1161/HYPERTENSIONAHA.119.14359

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 10.

    Ruhle BC, et al.. Keeping primary aldosteronism in mind: Deficiencies in screening at-risk hypertensives. Surgery 2019; 165:221227. doi: 10.1016/j.surg.2018.05.085

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 11.

    Sivarajah M, et al.. Adherence to consensus guidelines for screening of primary aldosteronism in an urban healthcare system. Surgery 2020; 167:211215. doi: 10.1016/j.surg.2019.05.087

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 12.

    Cohen JB, et al.. Testing for primary aldosteronism and mineralocorticoid receptor antagonist use among U.S. veterans: A retrospective cohort study. Ann Intern Med [published online ahead of print December 29, 2020]. doi: 10.7326/M20-4873; https://www.acpjournals.org/doi/10.7326/M20-4873

    • Search Google Scholar
    • Export Citation

Don’t Forget about the Other A in the RAAS; Primary Aldosteronism Is More Common Than You Think

  • 1 James Brian Byrd, MD, MS, is Assistant Professor of Internal Medicine, Division of Cardiovascular Medicine, University of Michigan Medical School, Ann Arbor. Jordana B. Cohen, MD, MSCE, is Assistant Professor of Medicine and Epidemiology, Renal-Electrolyte and Hypertension Division, Perelman School of Medicine, University of Pennsylvania, Philadelphia.
Restricted access
Save